Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.39 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20052009 | 0.82 | CCNB2 (0.44) | CCNB2CDK1CCNB1CCNB3AHCY | |
| SCHEMBL13952071 | 0.80 | CDK5 (0.35) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL20052010 | 0.78 | CCNB2 (0.40) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL13896532 | 0.76 | AHCY (0.40) | CCNB2CDK1CCNB1CCNB3AHCY | |
| SCHEMBL16417876 | 0.73 | CDK5 (0.35) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL20052944 | 0.73 | AHCY (0.43) | CCNB2CDK1CCNB1CCNB3AHCY | |
| SCHEMBL13896531 | 0.72 | CCNB2 (0.37) | CCNB2CDK1CCNB1CCNB3AHCY | |
| SCHEMBL15426097 | 0.72 | CCNB2 (0.42) | CCNB2CDK1CCNB1CCNB3CDK2 | |
| SCHEMBL13443481 | 0.72 | TDP1 (0.41) | CCNB2CDK1CCNB1CCNB3AHCY | |
| SCHEMBL17552180 | 0.70 | AHCY (0.39) | CDK5CDK5R1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | FUJITSU LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053710-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | TACR1, TACR2, ATIC | CDK5 2371/4885CDK5R1 2061/4885CCNB2 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.